Dr. Jonathan Schoenfeld of Synergy of Chemotherapy and Immunotherapy in Head and Neck Cancer
Jonathan Schoenfeld, MD, MPH, discusses the immunologic effects of chemotherapy plus radiation, as well as radiation alone.
Jonathan Schoenfeld, MD, MPH, attending radiation oncologist, assistant professor, Harvard Medical School, Dana Farber Cancer Institute/Brigham and Women's Hospital, discusses the immunologic effects of chemotherapy plus radiation, as well as radiation alone.
Schoenfeld says he and his team looked at chemokines, part of the cytokines family, and their mediation abilities outside the treatment field, as well as circulating T cells. He adds that some T cells investigated included CD8-positive T cells, CD4-positive T cells, as well as markers of active T cells and T regulatory cells.
Schoenfeld says chemotherapy and radiation have long been used for their immune suppressive effects, though chemotherapy and radiation given in a certain way can cause immunologic cell death. This ability could synergize with immunotherapy and immune checkpoint blockade treatments currently being developed.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
